Tarsus Pharmaceuticals, Inc. Cash Flow Statement

Cash Flow Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -26.81M-13.83M-62.09M-135.89M-115.55M
Depreciation and Depletion 0.04M0.10M0.30M0.33M0.74M0.70M
Share-based Compensation 0.02M3.12M8.46M13.46M19.83M27.82M
Gains from Investment Securities 0.16M0.73M2.27M0.21M1.85M-0.57M
Asset Writedowns and Impairment 0.01M0.00M
Cash from Operations -3.67M-21.14M3.75M-49.03M-117.49M-83.03M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.04M0.15M0.29M1.32M3.16M4.21M
Amortization of Deferred Charges 0.31M0.39M0.48M
Depreciation & Amortization (CF) 0.04M0.10M0.31M0.33M0.74M0.70M
Change in Working Capital
Change in Receivables 0.03M-0.02M0.07M3.49M16.62M30.14M
Change in Inventory 3.11M2.05M
Change in Accured Expenses 0.30M3.24M3.88M2.72M13.24M40.34M
Other Working Capital Changes 0.02M2.46M2.04M0.72M2.89M7.02M
Investing Activities
Capital Expenditures 0.17M0.46M0.59M0.51M1.50M1.57M
Change in Intangibles 4.00M5.00M
Change in Acquisitions & Divestments 5.32M174.77M73.00M
Cash from Investing Activities -0.17M-0.46M-0.59M-144.63M140.60M-199.19M
Financing Activities
Other financing activities 0.17M2.44M0.88M3.52M
Cash from Financing Activities 59.45M131.77M0.02M93.99M130.18M154.66M
Additional items
Change in Cash 55.60M110.18M3.18M-99.67M153.29M-127.57M
Free Cash Flow -3.85M-21.59M3.16M-49.54M-119.00M-84.59M
Net Cash Flow 55.60M110.18M3.18M-99.67M153.29M-127.57M